Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia

NCT02110394 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.

NCT NCT02110394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02110394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia
Lead sponsor
Astellas Pharma Europe B.V.
Phase
Observational
Overall status
Completed
Start date
June 30, 2012
Completion date
August 31, 2015
Enrollment
190 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia